SCHEMBL30822092

SCHEMBL30822092

CCOc1cc2ncnc(Nc3cc(Br)ccc3OC)c2cc1OC1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 14/20 0.56
▸ EPHA2 P29317 3/20 0.55
▸ ERBB2 P04626 7/20 0.54
▸ PDE4A P27815 1/20 0.51
▸ PDE4B Q07343 1/20 0.51
▸ PDE4C Q08493 1/20 0.51
▸ PDE4D Q08499 1/20 0.51
▸ EPHB4 P54760 2/20 0.51
▸ RIPK2 O43353 1/20 0.51
▸ RET P07949 1/20 0.51
▸ MET P08581 1/20 0.51
▸ EPHB2 P29323 1/20 0.51
▸ TEC P42680 1/20 0.51
▸ EPHA4 P54764 1/20 0.51
▸ BTK Q06187 1/20 0.51
▸ KCNH2 Q12809 1/20 0.51
▸ TNK1 Q13470 1/20 0.51
▸ RIPK3 Q9Y572 1/20 0.51
▸ KDR P35968 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27136650 1.00 EGFR (0.56) EGFREPHA2ERBB2PDE4APDE4B
SCHEMBL27152211 0.95 EGFR (0.62) EGFREPHA2ERBB2EPHB4RIPK2
SCHEMBL30820508 0.95 EGFR (0.62) EGFREPHA2ERBB2EPHB4RIPK2
SCHEMBL27154368 0.90 EGFR (0.60) EGFRERBB2EPHB4RIPK2RET
SCHEMBL30032119 0.86 EPHA2 (0.57) EGFREPHA2ERBB2
SCHEMBL30030964 0.86 EGFR (0.52) EGFREPHA2ERBB2EPHB4RIPK2
SCHEMBL27148662 0.86 EPHA2 (0.57) EGFREPHA2ERBB2
SCHEMBL30820474 0.86 EPHA2 (0.57) EGFREPHA2ERBB2
SCHEMBL24714566 0.86 EPHA2 (0.52) EGFREPHA2ERBB2PDE4APDE4B
SCHEMBL22244931 0.83 EGFR (0.68) EGFRERBB2EPHB4RIPK2RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240246940-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC. (KR) 2024-07-25 — — US disclosed
EP-4328222-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-02-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246940-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF ERBB2, EGFR, ERBB3 EGFR 2/4885EPHA2 25/4885ERBB2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback